PLYMOUTH, Minn.--(BUSINESS WIRE)--Sage Medical Technologies, Inc (Sage Medical) presented at the In3 East Investor Conference yesterday in Boston, MA. Sage Medical is an early stage medical device company developing its core endovascular technology to address two deficits of the aorta. The company is completing animal studies with a plan to initiate human feasibility trials in the first quarter of 2008.
"We are delighted with the rapid progress of our research & development team in producing a functional prototype and its evaluation in animals. The timeline from product sketch to implant has been an impressive six months. Augmenting this is enthusiastic guidance from key opinion leaders in both the cardiology and vascular surgery communities," said Jagi Gill, Chief Executive Officer.
The first program of the company is focused on aortic dissection, a condition which develops acutely as a tear in the aortic wall leading to rapid blood loss. Current surgical and medical treatments have a mortality rate of over 30 %. A minimally invasive approach designed specifically to treat aortic dissections offers a much needed solution to this catastrophic disease. Over 35,000 patients per year in the US would be candidates for use of the Sage Medical system.
The core technology is also being developed to provide a catheter-based solution to entrap plaque which resides in the aortic arch. Aortic plaque has been documented to contribute to 15-25 % of all ischemic strokes. Much like the growth in carotid artery stenting to reduce the incidence of stroke for appropriate patients, the safe deployment of the Sage Medical plaque-entrapping stent should reduce the risk of stroke in over 130,000 persons in the US who annually present with aortic arch plaque.
Sage Medical is actively raising funds for its Series B financing. This will permit for the completion of animal work and initial human studies for both clinical programs.
About Sage Medical Technologies, Inc
Sage Medical has been in operations since January 2006 in its facility outside of Minneapolis, MN. The company's proprietary and patent pending technologies combine an ultra-flexible nitinol stent, macro-porous covering to promote vessel healing along with a unique user-friendly catheter delivery system. While conventional stent-grafts do not permit for accurate deployment around the aortic arch, the Sage Medical system is designed to enable the endovascular surgeon to do so in a percutaneous manner.
More information regarding Sage Medical can be found by calling the company at 763-746-0240 or by email at firstname.lastname@example.org.
Jagi Gill, Chief Executive Officer, 763-746-0240
Source: Sage Medical
>>> Discuss This Story